Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108)

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Heparin sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

What it is and what it is used for

for Heparin belongs to a group of drugs that are called anticoagulants. These help to stop blood clotting. Heparin injection 5,000 I.U./ml or 25,000 I.U./ml is used in conditions where blood vessels may become blocked by blood clots. It is therefore used to treat and prevent:

  • blood clots in leg veins (deep vein thrombosis)
  • blood clots in the lung (pulmonary embolism) as well as for:
  • the treatment of chest pains resulting from disease of the heart arteries (unstable angina pectoris)
  • the treatment of severe blockages affecting arteries in the legs (acute peripheral arterial occlusion)
  • the prevention of blood clots in the heart following a heart attack (mural thrombosis). It is also used during heart and lung operations and during kidney dialysis.

What you need to know before you take it

Heparin Injection This medicine should not be injected into your muscles This medicine should not be used after major trauma Heparin injection should not be given if you:

  • are allergic to heparin or any of the other ingredients of this medicine (listed in section 6)
  • drink large amounts of alcohol
  • are currently bleeding from anywhere in the body, (apart from your normal period which does not stop you being given heparin injection)
  • have haemophilia (a genetic disorder which may cause you to bleed excessively) or any other bleeding problem
  • have or have ever had thrombocytopenia (a serious blood disorder which prevents blood from clotting properly)
  • bruise easily (fragile capillaries) or have lots of purple spots that look like bruises (purpura)
  • have very high blood pressure
  • are suffering from tuberculosis (TB)
  • have had severe skin problems resulting from previous heparin treatment
  • are about to have surgery of the brain, spine or eye, a lumbar puncture or local anaesthetic nerve block, or some other procedure where bleeding could be a problem
  • have recently had an operation
  • suffer from severe liver problems which can lead to bleeding into the oesophagus (gullet)
  • have bleeding into the brain.
  • are about to be treated for pain and inflammation with intravenous diclofenac Important: If you are having an epidural or spinal anaesthetic You must remind your doctor that you are having heparin before you receive any anaesthetic. After you have the anaesthetic your doctor or nurse will make regular checks. This is to check if you are getting any major bleeding or bruising around your spine. This may cause paralysis that could be permanent. Any signs this may be happening to you include tingling, weakness or numbness in your lower legs or body, back pain or problems in going to the toilet. This happens very rarely. After you have the anaesthetic your doctor will tell you when you can take your medicine again. Warnings and precautions Heparin injection must not be given to premature or newborn babies. Talk to your doctor before heparin injection is given if you:
  • are over 60 years of age
  • have any condition which makes you likely to bleed more easily (for example a stomach ulcer, hiatus hernia, inflammation of the heart, problems in the back of your eye, haemorrhoids (piles), a stroke, cancer or threatened miscarriage), If you are unsure, ask your doctor or nurse.
  • suffer from diabetes
  • suffer from excess acid or high levels of potassium in your blood or are taking a medicine that may increase the potassium level in your blood (e.g. amiloride, triamterene, eplerenone or spironolactone). If any of these apply you may need to have a blood test before the start of your heparin treatment. If you are unsure, ask your doctor or nurse
  • have kidney or liver disease. Your doctor may decide that a lower dose is necessary
  • suffer from allergies or have previously had an allergic reaction to low molecular weight (LMW)

Information for Health Care Professionals Heparin sodium 5,000 I.U./ml solution for injection or concentrate for solution for infusion Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion Qualitative and Quantitative Composition Heparin sodium 5,000 I.U./ml – Heparin sodium 5,000 I.U./ml (25,000 I.U. in 5ml) Heparin sodium 25,000 I.U./ml – Heparin sodium 25,000 I.U./ml (125,000 I.U. in 5ml) For the full list of excipients, see section 6.1. Posology and method of administration Route of administration By continuous intravenous infusion in 5% glucose or 0.9% sodium chloride or by intermittent intravenous injection, or by subcutaneous injection. The intravenous injection volume of heparin injection should not exceed 15ml. As the effects of heparin are short-lived, administration by intravenous infusion or subcutaneous injection is preferable to intermittent intravenous injections. Recommended dosage Prophylaxis of deep vein thrombosis and pulmonary embolism: Adults: 2 hours pre-operatively: 5,000 units subcutaneously Followed by: 5,000 units subcutaneously every 8-12 hours, for 7-10 days or until the patient is fully ambulant. No laboratory monitoring should be necessary during low dose heparin prophylaxis. If monitoring is considered desirable, anti-Xa assays should be used as the activated partial thromboplastin time (APTT) is not significantly prolonged. During pregnancy: 5,000 – 10,000 units every 12 hours, subcutaneously, adjusted according to APTT or anti-Xa assay. Elderly: Dosage reduction and monitoring of APTT may be advisable.

Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.

heparin. A small test dose of heparin sodium injection may be given first.

  • if you are taking another medicine that may affect your blood clotting. For a list of these medicines see the section ''Other medicines and Heparin Injection''. Your doctor will check your blood if you receive treatment for longer than five days and may do other blood tests if you have major surgery. Your doctor may take a blood test up to several weeks after the end of your heparin treatment. This is so the doctor can check the level of the clotting cells (platelets) in your blood. Your doctor will take particular care if:
  • the patient is an infant or child under three years old
  • you have an epidural or an anaesthetic given into the spine. After an epidural or an anaesthetic is given into the spine, your doctor or nurse will make regular checks for signs of tingling, weakness or numbness in your lower legs or body, back pain or problems in going to the toilet. You should alert your doctor or nurse if you experience any of these. Other medicines and Heparin Injection Tell your doctor if you are taking, have recently taken or might take any other medicines, including those medicines obtained without a prescription, as some medicines may affect the way heparin injection works. Taking some medicines at the same time as heparin may mean you may be likely to bleed more. In particular, tell your doctor if you are taking any of the following:
  • aspirin or other non-steroidal anti-inflammatory drugs (e.g ketorolac, diclofenac or ibuprofen)
  • dextran solutions (used to treat shock)
  • medicines which may interfere with the proper clotting of the blood (e.g. dipyridamole, epoprostenol, clopidogrel or streptokinase)
  • cephalosporins, used to treat infections
  • ACE inhibitors (e.g. captopril enalapril, lisinopril, ramipril), angiotensin II antagonists (e.g. losartan or valsartan) or a renin inhibitor drug called aliskiren, used for treating high blood pressure or heart problems
  • medicines that may increase the potassium level in your blood (e.g. amiloride, triamterene, eplerenone or spironolactone)
  • glyceryl trinitrate given into a vein (for coronary heart disease)
  • aminoglycoside antibiotics (e.g. gentamicin, amikacin, neomycin or tobramycin)
  • probenecid, used in the treatment of gout If you need one of the above medicines your doctor may decide to alter the dose of heparin injection or the other medication. If you have any doubts about whether this medicine should be administered then discuss things more fully with your doctor or nurse before it is given. Tobacco smoke can also interfere with the working of heparin injection. You should inform your doctor if you smoke. The presence of heparin in the blood can affect the results of some blood tests such as thyroid tests and the levels of calcium or some antibiotics (e.g. gentamicin) in the blood. Important information about the ingredients Benzyl alcohol This medicine contains 10mg/ml benzyl alcohol. Benzyl alcohol may cause allergic reactions. Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called ''gasping syndrome'') in young children. Do not give to your newborn baby (up to 4 weeks old), unless recommended by your doctor. Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor or pharmacist. Large amounts of benzyl alcohol can build up in pregnant or breastfeeding women. This may cause side effects (called ''metabolic acidosis''). This side effect can also be seen in people with liver or kidney disease. Methyl parahydroxybenzoate The methyl parahydroxybenzoate in heparin injection may cause allergic reactions (possibly delayed) and exceptionally bronchospasm Pregnancy, breast-feeding and fertility You should let your doctor or nurse know before you are given heparin injection if you are pregnant, wish to become pregnant or have a history of, or known risk to miscarriage. If you are being given heparin injection bleeding may be a problem during pregnancy or after delivery. Your bones may get thinner if you receive heparin for a long time during pregnancy. If you are pregnant and are going to have an epidural anaesthetic, you should stop having your medicine. Ask your doctor for advice. Ask your doctor or nurse for advice if you wish to breast-feed Driving and using machines Heparin injection has not been reported to affect ability to drive or operate machines. 3. How Heparin Injection should be given Your doctor or nurse will inject your dose of heparin into a vein either all at once or over a longer period of time (usually via a drip). Alternatively they may inject your heparin underneath your skin. The amount injected all at once into a vein should not be greater than 15ml. You may need to have blood tests if you are receiving higher doses of heparin or if you are pregnant to check on the effects of your heparin treatment. Heparin injection must not be given to premature or newborn babies. You may require a lower dose if you have kidney or liver disease. To PREVENT blood clots in leg veins (deep vein thrombosis) and blood clots in the lung (pulmonary embolism) Adults The usual dose of heparin injection in adults is 5,000 units injected under the skin 2 hours before your operation, followed by 5,000 units injected under the skin every 8-12 hours, for 7-10 days or until you are fully able to move about.

Children: No dosage recommendations. Treatment of deep vein thrombosis and pulmonary embolism: Adults: Loading dose: 5,000 units intravenously (10,000 units may be required in severe pulmonary embolism) Maintenance: 1,000-2,000 units/hour by intravenous infusion, or 10,000-20,000 units 12 hourly subcutaneously, or 5,000-10,000 units 4-hourly by intravenous injection. Elderly: Dosage reduction may be advisable. Children and small adults: Loading dose: 50 units/kg intravenously Maintenance: 15-25 units/kg/hour by intravenous infusion, or 250 units/kg 12 hourly subcutaneously or 100 units/kg 4-hourly by intravenous injection Treatment of unstable angina pectoris and acute peripheral arterial occlusion: Adults: Loading dose: 5,000 units intravenously Maintenance: 1,000-2,000 units/hour by intravenous infusion, or 5,000-10,000 units 4-hourly by intravenous injection. Elderly: Dosage reduction may be advisable. Children and small adults: Loading dose: 50 units/kg intravenously Maintenance: 15-25 units/kg/hour by intravenous infusion, or 100 units/kg 4-hourly by intravenous injection Daily laboratory monitoring (ideally at the same time each day, starting 4-6 hours after initiation of treatment) is essential during full-dose heparin treatment, with

Customer

Wockhardt UK Limited

Colours Used

Description

Heparin sodium 5000i.u/ml leaflet

Black

Item Code

106923/5

Keyline (Non-Printing)

Profile

As current

Text Free Area (Non-Printing)

Size

560 x 148mm

Min.Point Size

Other

Market

UK

Language

English

Standard 319

Barcode Proof By

GKE

Proof No.

1

Date

28/01/2022

Body Text Fonts:

Myriad Pro

Body Text Ctd.

Cirrus_Info_Box Actual Min Point Size

7pt

Pregnancy During pregnancy the dosage is 5,000-10,000 units injected under the skin every 12 hours. The dose may be adjusted according to your blood tests. Elderly Lower doses may be used in the elderly. You may need to have blood tests if you are elderly, to check on the effects of your heparin treatment. Children No specific doses are recommended. To TREAT blood clots in leg veins (deep vein thrombosis) and blood clots in the lung (pulmonary embolism). Adults The usual dose in adults is 5,000 units injected into a vein. This is followed by:

  • 1,000-2,000 units/hour injected slowly into a vein or
  • 10,000-20,000 units 12 hourly injected under the skin or
  • 5,000-10,000 units 4 hourly injected all at once into a vein Elderly Lower doses may be used in the elderly Small adults and children Small adults and children will be given 50 units/kg body weight injected into a vein followed by:
  • 15-25 units/kg body weight/hour injected slowly into a vein or
  • 250 units/kg body weight 12 hourly injected under the skin or
  • 100 units/kg body weight 4 hourly injected all at once into a vein To TREAT chest pains (unstable angina pectoris) and severe blood clots in the arteries (acute peripheral arterial occlusion) Adults The usual dose in adults is 5,000 units injected into a vein. This is followed by:
  • 1,000-2,000 units/hour injected slowly into a vein or
  • 5,000-10,000 units 4 hourly injected all at once into a vein Elderly Lower doses may be used in the elderly Small adults and children Small adults and children will be given 50 units/kg body weight injected into a vein followed by:
  • 15-25 units/kg body weight/hour injected slowly into a vein or
  • 100 units/kg body weight 4 hourly injected all at once into a vein You will have blood tests every day to check the effects of your heparin To prevent a blood clot in the heart following a heart attack. Adults The usual dose for adults is 12,500 units 12 hourly injected under the skin for at least 10 days. Elderly A lower dose may be needed. During Heart and Lung Surgery (Adults) Initially you will be given 300 units/kg body weight. This will be changed according to the results of your blood tests. During kidney dialysis (Adults) Initially you will be given 1,000-5,000 units. This will be changed according to the results of your blood tests. If you think you have been given too much heparin injection Your doctor will decide which dose is best for you. Too much heparin can cause bleeding. Slight bleeding can be stopped by stopping your heparin treatment. However if you have more severe bleeding you may need blood tests and an injection of a medicine called protamine sulfate. If you think too much medicine has been given to you contact your doctor or nurse. 4. Possible side effects Like all medicines, heparin injection can cause side effects, although not everybody gets them. These are most likely to occur when treatment is first started. You should inform your doctor or nurse immediately if you feel unwell. Important side effects to look out for:
  • Severe allergic reactions
  • allergic reactions including an itchy skin, rash, eye irritation, runny nose, wheezing, rapid breathing, a blue tinge to the lips, fever, chills, swelling of the eyes and lips, and shock. Allergic reactions may be due to the ingredients in your heparin rather than the heparin itself. This occurs particularly in infants or children up to three years old. If you think you are having a severe allergic reaction (see symptoms above) you must tell your doctor or nurse immediately.
  • Bleeding and Bruising Heparin injection can reduce the number of cells that help your blood clot (thrombocytopenia) and so can cause bleeding and bruising. This is most likely to occur within the first few days of treatment but may occur later too. The risk of bleeding is increased in the elderly (particularly elderly women). Thrombocytopenia may result in the formation of dangerous blood clots causing chest pains, shortness of breath, coughing, feeling faint, dizziness or loss of consciousness. If thrombocytopenia develops, Heparin treatment should be stopped immediately. Thrombocytopenia can occur up to several week after the end of your heparin treatment. As such, your doctor may take a blood test in that time. This is so the doctor can check the level of the clotting cells (platelets) in your blood. Signs that you are bleeding more easily include:
  • unusual bruising or purple spots on your skin
  • unusual bleeding from your gums
  • unusual nose bleeds
  • blood in your urine (which may cause this to go dark)
  • black, tarry-looking stools
  • bleeding that will not stop from any operation site or other injury. If you are concerned about unusual bleeding you must tell your doctor or nurse immediately as you may need to stop your heparin.
  • signs of developing paralysis (After having an epidural or spinal anaesthetic)

adjustment of dosage to maintain an APTT value 1.5-2.5 x midpoint of normal range or control value. Prophylaxis of mural thrombosis following myocardial infarction Adults: 12,500 units 12 hourly subcutaneously for at least 10 days. Elderly: Dosage reduction may be advisable In extracorporeal circulation and haemodialysis Adults: Cardiopulmonary bypass: Initially 300 units/kg intravenously, adjusted thereafter to maintain the activated clotting time (ACT) in the range 400-500 seconds. Haemodialysis and haemofiltration: Initially 1,000-5,000 units, Maintenance: 1,000-2,000 units/hour, adjusted to maintain clotting time >40 minutes. Heparin resistance Patients with altered heparin responsiveness or heparin resistance may require disproportionately higher doses of heparin to achieve the desired effect. Also refer to section 4.4, Special warnings and precautions for use. List of excipients Benzyl alcohol Methyl parahydroxybenzoate (E218) Water for injections Sodium hydroxide solution Hydrochloric acid Incompatibilities Heparin is incompatible with many injectable preparations e.g. some antibiotics, opioid analgesics and antihistamines. The following drugs are incompatible with heparin; Alteplase, amikacin sulfate, amiodarone hydrochloride, ampicillin sodium, aprotinin, benzylpenicillin potassium or sodium, cefalotin sodium, chlorpromazine hydrochloride, ciprofloxacin lactate, cisatracurium besilate, cytarabine, dacarbazine, daunorubicin hydrochloride, diazepam,

Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.

Signs of developing paralysis include: o tingling, weakness or numbness in your legs or lower body o back pain o incontinence of urine or incontinence from back passage or other problem in those areas You must get urgent medical help if you have any of these symptoms following an epidural or spinal anaesthetic. Other side effects include: Common: may affect up to 1 in 10 people

  • red lumps or red, itchy patches like eczema often develop 3-21 days after the start of heparin treatment, where injections have been given under the skin Rare: may affect up to 1 in 1,000 people
  • raised levels of potassium in the blood, particularly in patients with kidney failure or diabetes. If affected you may feel tired and weak.
  • irritation or sloughing of skin which may occur around the injection site. Not known; frequency cannot be estimated from the available data
  • loss of hair (alopecia) if heparin sodium injection is given over many months
  • weakening of the bones (osteoporosis) if heparin sodium injection is given over many months
  • fractures of the spine and ribs if heparin is given over many months
  • persistent erection of the penis (priapism)
  • abnormal liver tests
  • the amount of a hormone called aldosterone may be lower than normal Your doctor can explain this more.
  • high lipid levels on stopping heparin Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible

How to take it

4. Possible side effects 5. How to store heparin injection 6. Contents of the pack and other information

Possible side effects

not listed in this leaflet. You can also report side effects directly via the national reporting systems listed below. United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to store it

Heparin Injection Keep this medicine out of the sight and reach of children. Your doctor or nurse will usually be responsible for storing and preparing heparin injection before use and for checking that the vials have not passed their expiry date stated on the carton and the label. Do not use this medicine after the expiry date which is stated on the carton and the label. The expiry date refers to the last day of that month. Heparin injection should not be given if it shows signs of deterioration such as discolouration. Do not store above 25°C. Store in the original packaging in order to protect the product from light. After opening, heparin vials may be kept for 28 days at 25°C, after which they should be discarded. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What heparin injection contains The active substance is heparin sodium. 1ml of solution of heparin sodium injection 5,000 I.U./ml contains 5,000 international units of the active ingredient. It is available in 5ml multidose vials containing 25,000 I.U. in 5ml of solution. 1ml of solution of heparin sodium injection 25,000 I.U./ml contains 25,000 international units of the active ingredient. It is available in 5ml multidose vials containing 125,000 I.U. in 5ml of solution. The other ingredients include benzyl alcohol (10mg/ml), methyl parahydroxybenzoate (E218), water for injections, hydrochloric acid and sodium hydroxide. What heparin injection looks like and contents of the pack Heparin injection is a colourless or straw-coloured liquid. Each carton contains 10 glass vials. Other formats To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK Only) Please be ready to give the following information: Product Name Heparin sodium 5,000 I.U./ml solution for injection or concentrate for solution for infusion Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion

Reference Number 29831/0110

29831/0108

This is a service provided by the Royal National Institute of Blind People. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK. Manufacturer: CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF, UK. This leaflet was last revised in 01/2022

106923/5

doxorubicin hydrochloride, droperidol, erythromycin lactobionate, gentamicin sulfate, haloperidol lactate, hyaluronidase, hydrocortisone sodium succinate, kanamycin sulfate, labetolol hydrochloride, levofloxacin, methicillin sodium, methotrimeprazine, netilmicin sulfate, nicardipine hydrochloride, oxytetracycline hydrochloride, pethidine hydrochloride, polymyxin B sulfate, promethazine hydrochloride, streptomycin sulfate, tobramycin sulfate, triflupromazine hydrochloride, vancomycin hydrochloride, vinblastine sulfate and vinorelbine tartrate. Dobutamine hydrochloride and heparin should not be mixed or infused through the same intravenous line, as this causes precipitation. Heparin and reteplase are incompatible when combined in solution. If reteplase and heparin are to be given through the same line this, together with any Y-lines, must be thoroughly flushed with a 0.9% saline or a 5% glucose solution prior to and following the reteplase injection. Shelf life 3 years Chemical and physical in use stability has been demonstrated for 28 days at 25°C. From a microbiological point of view, once opened, the product may be stored for a maximum of 28 days at 25°C. Other in use storage times and conditions are the responsibility of the user. Special precautions for storage Do not store above 25°C. Store in the original package Special precautions for disposal Each multidose vial should be restricted to use in a single patient. This leaflet was last revised in January 2022

106923/5

Customer

Wockhardt UK Limited

Colours Used

Description

Heparin sodium 5000i.u/ml leaflet

Black

Item Code

106923/5

Keyline (Non-Printing)

Profile

As current

Text Free Area (Non-Printing)

Size

560 x 148mm

Min.Point Size

Other

Market

UK

Language

English

Standard 319

Barcode Proof By

GKE

Proof No.

1

Date

28/01/2022

Body Text Fonts:

Myriad Pro

Body Text Ctd.

Cirrus_Info_Box Actual Min Point Size

7pt

Frequently asked questions about Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108)

How do I take Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108)?

Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108) comes as injection. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108)?

The active substance in Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108) is heparin sodium.

Are there equivalent medicines to Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108)?

Medicines with the same active substance, strength and form include: Heparin 5,000 I.U./ml Solution for injection (with preservative), Heparin Sodium 5,000 I.U./ml Solution for injection (without preservative), Heparin calcium 25,000 I.U./ml Solution for injection or concentrate for solution for infusion (PL 29831/0104). In total there are 8 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108) without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Heparin sodium (19 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Prophylaxis of deep vein thrombosis and pulmonary embolism

Treatment of deep vein thrombosis, pulmonary embolism, unstable angina pectoris and acute peripheral arterial occlusion.

Prophylaxis of mural thrombosis following myocardial infarction.

In extracorporeal circulation and haemodialysis.

4.2. Posology and method of administration

Route of administration

By continuous intravenous infusion in 5% glucose or 0.9% sodium chloride or by intermittent intravenous injection, or by subcutaneous injection.

The intravenous injection volume of heparin injection should not exceed 15ml.

As the effects of heparin are short-lived, administration by intravenous infusion or subcutaneous injection is preferable to intermittent intravenous injections.

Recommended dosage

Prophylaxis of deep vein thrombosis and pulmonary embolism:

Adults:

2 hours pre-operatively:

followed by:

5,000 units subcutaneously

5,000 units subcutaneously every 8-12 hours, for 7-10 days or until the patient is fully ambulant.

No laboratory monitoring should be necessary during low dose heparin prophylaxis. If monitoring is considered desirable, anti-Xa assays should be used as the activated partial thromboplastin time (APTT) is not significantly prolonged.

During pregnancy:

5,000 - 10,000 units every 12 hours, subcutaneously, adjusted according to APTT or anti-Xa assay.

Elderly:

Dosage reduction and monitoring of APTT may be advisable.

Children:

No dosage recommendations.

Treatment of deep vein thrombosis and pulmonary embolism:

Adults:

Loading dose:

5,000 units intravenously (10,000 units may be required in severe pulmonary embolism)

Maintenance:

1,000-2,000 units/hour by intravenous infusion,

or 10,000-20,000 units 12 hourly subcutaneously,

or 5,000-10,000 units 4-hourly by intravenous injection.

Elderly:

Dosage reduction may be advisable.

Children and small adults:

Loading dose:

50 units/kg intravenously

Maintenance:

15-25 units/kg/hour by intravenous infusion,

or 250 units/kg 12 hourly subcutaneously

or 100 units/kg 4-hourly by intravenous injection

Treatment of unstable angina pectoris and acute peripheral arterial occlusion:

Adults:

Loading dose:

5,000 units intravenously

Maintenance:

1,000-2,000 units/hour by intravenous infusion,

or 5,000-10,000 units 4-hourly by intravenous injection.

Elderly:

Dosage reduction may be advisable.

Children and small adults:

Loading dose:

50 units/kg intravenously

Maintenance:

15-25 units/kg/hour by intravenous infusion,

or 100 units/kg 4-hourly by intravenous injection

Daily laboratory monitoring (ideally at the same time each day, starting 4-6 hours after initiation of treatment) is essential during full-dose heparin treatment, with adjustment of dosage to maintain an APTT value 1.5-2.5 x midpoint of normal range or control value.

Prophylaxis of mural thrombosis following myocardial infarction

Adults:

12,500 units 12 hourly subcutaneously for at least 10 days.

Elderly:

Dosage reduction may be advisable

In extracorporeal circulation and haemodialysis

Adults:

Cardiopulmonary bypass:

Initially 300 units/kg intravenously, adjusted thereafter to maintain the activated clotting time (ACT) in the range 400-500 seconds.

Haemodialysis and haemofiltration:

Initially 1-5,000 units,

Maintenance: 1-2,000 units/hour, adjusted to maintain clotting time >40 minutes.

Heparin resistance

Patients with altered heparin responsiveness or heparin resistance may require disproportionately higher doses of heparin to achieve the desired effect. Also refer to section 4.4, Special warnings and precautions for use.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the other excipients listed in section 6.1.

Must not be given to premature babies or neonates (contains benzyl alcohol).

Heparin should not be administered by intramuscular injection or after major trauma.

Patients who consume large amounts of alcohol, who are sensitive to the drug, who are actively bleeding or who have haemophilia or other bleeding disorders, severe liver disease (including oesophageal varices), purpura, severe hypertension, active tuberculosis or increased capillary permeability.

Patients with present or previous thrombocytopenia. The rare occurrence of skin necrosis in patients receiving heparin contra-indicates the further use of heparin either by subcutaneous or intravenous routes because of the risk of thrombocytopenia. Because of the special hazard of post-operative haemorrhage heparin is contra-indicated during surgery of the brain, spinal cord and eye, in procedures at sites where there is a risk of bleeding, in patients that have had recent surgery, and in patients undergoing lumbar puncture or regional anaesthetic block.

The relative risks and benefits of heparin should be carefully assessed in patients with a bleeding tendency or those patients with an actual or potential bleeding site eg. hiatus hernia, peptic ulcer, neoplasm, bacterial endocarditis, retinopathy, bleeding haemorrhoids, suspected intracranial haemorrhage, cerebral thrombosis or threatened abortion.

In patients receiving heparin for treatment rather than prophylaxis, locoregional anaesthesia in elective surgical procedures is contraindicated because use of heparin may be very rarely associated with epidural or spinal haematoma resulting in prolonged or permanent paralysis. If such a procedure is planned the heparin should be stopped and the procedure should be delayed until the aPTT has returned to normal. Epidural anaesthesia use during birth in pregnant women treated with heparin is contraindicated (see section 4.6).

Menstruation is not a contra-indication.

Concomitant use of intravenous diclofenac with heparin (including low dose heparin) is contraindicated.

4.4. Special warnings and precautions for use

Platelet counts should be measured in patients receiving heparin treatment for longer than 5 days and the treatment should be stopped immediately in those who develop thrombocytopenia.

Heparin induced thrombocytopenia (HIT) and heparin induced thrombocytopenia with thrombosis (HITT) can occur up to several weeks after discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT or HITT.

In patients with advanced renal or hepatic disease, a reduction in dosage may be necessary. The risk of bleeding is increased with severe renal impairment and in the elderly (particularly elderly women).

Although heparin hypersensitivity is rare, it is advisable to give a trial dose of 1,000 I.U. in patients with a history of allergy. Caution should be exercised in patients with known hypersensitivity to low molecular weight heparins.

In most patients, the recommended low-dose regimen produces no alteration in clotting time. However, patients show an individual response to heparin, and it is therefore essential that the effect of therapy on coagulation time should be monitored in patients undergoing major surgery.

Caution is recommended in patients receiving heparin prophylactically and undergoing spinal or epidural anaesthesia or spinal puncture (risk of spinal or epidural haematoma resulting in prolonged or permanent paralysis). The risk is increased by the use of a peridural or spinal catheter for anaesthesia, by the concomitant use of drugs affecting haemostasis such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors or anticoagulants and by traumatic or repeated puncture.

In decision making on the interval between the last administration of heparin at prophylactic doses and the placement or removal of a peridural or spinal catheter, the product characteristics and the patient profile should be taken into account. Subsequent dose should not take place before at least four hours have elapsed. Re-administration should be delayed until the surgical procedure is completed.

Should a physician decide to administer anticoagulation in the context of peridural or spinal anaesthesia, extreme vigilance and frequent monitoring must be exercised to detect any signs and symptoms of neurologic impairment, such as back pain, sensory and motor deficits and bowel or bladder dysfunction. Patients should be instructed to inform a nurse or clinician immediately if they experience any of these.

Heparin can suppress adrenal secretion of aldosterone leading to hyperkalemia, particularly in patients such as those with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, a raised plasma potassium, or taking potassium sparing drugs. The risk of hyperkalemia appears to increase with duration of therapy but is usually reversible. Plasma potassium should be measured in patients at risk before starting heparin therapy and in all patients treated for more than 7 days.

Heparin resistance

There is considerable variation in individual anticoagulant responses to heparin.

Heparin resistance, defined as an inadequate response to heparin at a standard dose for achieving a therapeutic goal occurs in approximately 5 to 30% of patients.

Factors predisposing to the development of heparin resistance, include:

• Antithrombin III activity less than 60% of normal (antithrombin III-dependent heparin resistance):

Reduced antithrombin III activity may be hereditary or more commonly, acquired (secondary to preoperative heparin therapy in the main, chronic liver disease, nephrotic syndrome, cardiopulmonary bypass, low grade disseminated intravascular coagulation or drug induced, e.g. by aprotinin, oestrogen or possibly nitroglycerin)

• Patients with normal or supranormal antithrombin III levels (antithrombin III-independent heparin resistance)

• Thromboembolic disorders

• Increased heparin clearance

• Elevated levels of heparin binding proteins, factor VIII, von Willebrand factor, fibrinogen, platelet factor 4 or histidine-rich glycoprotein

• Active infection (sepsis or endocarditis)

• Preoperative intra-aortic balloon counterpulsation

• Thrombocytopenia

• Thrombocytosis

• Advanced age

• Plasma albumin concentration ≤ 35g/dl

• Relative hypovolaemia

Heparin resistance is also often encountered in acutely ill patients, in patients with malignancy and during pregnancy or the post-partum period.

Drugs affecting platelet function or the coagulation system should in general not be given concomitantly with heparin (see section 4.5).

Heparin Injection contain Benzyl alcohol and Methyl parahydroxybenzoate

Benzyl alcohol

This medicine contains 10mg/ml benzyl alcohol. Benzyl alcohol may cause allergic reactions.

Benzyl alcohol has been linked with the risk of severe side effects including breathing problems (called ''gasping syndrome'') in young children.

Do not give to your newborn baby (up to 4 weeks old), unless recommended by your doctor.

Do not use for more than a week in young children (less than 3 years old), unless advised by your doctor.

Large amounts of benzyl alcohol can build up in pregnant or breast feeding women which may cause side effects (called ''metabolic acidosis''). This side effect can also be seen in people with liver or kidney disease.

Methyl parahydroxybenzoate

The methyl parahydroxybenzoate in heparin injection may cause allergic reactions (possibly delayed) and exceptionally bronchospasm

4.5. Interaction with other medicinal products and other forms of interaction

Analgesics: Drugs that interfere with platelet aggregation eg. aspirin and other NSAIDs should be used with care. Increased risk of haemorrhage with;

- Ketorolac

- Intravenous diclofenac (refer to section 4.3)

Avoid concomitant use of either ketorolac or intravenous diclofenac, even with low-dose heparin.

Anticoagulants, platelet inhibitors, etc: Increased risk of bleeding with oral anticoagulants, epoprostenol, clopidogrel, ticlopidine, streptokinase, dipyridamole, dextran solutions, abciximab, eptifibatide or any other drug which may interfere with coagulation.

Cephalosporins: Some cephalosporins, e.g. cefaclor, cefixime and ceftriaxone, can affect the coagulation process and may therefore increase the risk of haemorrhage when used concurrently with heparin.

ACE inhibitors, angiotensin-II receptor antagonists or the renin inhibitor aliskiren: Hyperkalaemia may occur with concomitant use.

Nitrates: Reduced activity of heparin has been reported with simultaneous intravenous glyceryl trinitrate infusion.

Probenecid: May increase the anticoagulant effects of heparin.

Tobacco smoke: Nicotine may partially counteract the anticoagulant effect of heparin. Increased heparin dosage may be required in smokers.

Interference with diagnostic tests may be associated with pseudo-hypocalcaemia (in haemodialysis patients), artefactual increases in total thyroxine and triiodothyronine, simulated metabolic acidosis and inhibition of the chromogenic lysate assay for endotoxin. Heparin may interfere with the determination of aminoglycosides by immunoassays.

4.6. Fertility, pregnancy and lactation

Heparin is not contraindicated in pregnancy. Heparin does not cross the placenta or appear in breast milk. The decision to use heparin in pregnancy should be taken after evaluation of the risk/benefit in any particular circumstances.

Osteoporosis has been reported with prolonged heparin treatment during pregnancy.

Particular caution is required at the time of delivery. Due to the risk of uteroplacental haemorrhage, heparin treatment should be stopped at the onset of labour.

If epidural anaesthesia is envisaged, heparin treatment should be suspended whenever possible.

Use in women with threatened abortion is contraindicated (refer to section 4.3).

4.7. Effects on ability to drive and use machines

None stated.

4.8. Undesirable effects

Blood disorders:

Haemorrhage (see also Special Warnings and Precautions and Overdosage Information).

Thrombocytopenia has been observed occasionally (see also Special Precautions and Warnings). It has been reported that thrombocytopenia occurs more frequently with bovine-derived heparin than porcine-derived heparin. Two types of heparin-induced thrombocytopenia have been defined. Type I is frequent, mild (usually >50 x 109/L) and transient, occurring within 1-5 days of heparin administration. Type II is less frequent but often associated with severe thrombocytopenia (usually <50 x 109/L). It is immune-mediated and occurs after a week or more (earlier in patients previously exposed to heparin). It is associated with the production of a platelet-aggregating antibody and thromboembolic complications, due to platelet-rich thrombi (the 'white clot syndrome'), which may precede the onset of thrombocytopenia. Pulmonary embolism has been reported as thromboembolic complications of heparin-induced thrombocytopenia. Heparin should be discontinued immediately in patients who develop thrombocytopenia.

Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis (HITT) can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.

Endocrine disorders:

Adrenal insufficiency secondary to adrenal haemorrhage has been associated with heparin (rarely). Heparin products can cause hypoaldosteronism which may result in an increase in plasma potassium. Rarely, clinically significant hyperkalemia may occur particularly in patients with chronic renal failure and diabetes mellitus (see Warnings and Precautions).

Hepatic disorders:

Increased serum transaminase values may occur but usually resolve on discontinuation of heparin.

Immune system disorders:

Hypersensitivity reactions to heparin are rare. They include urticaria, conjunctivitis, rhinitis, asthma, cyanosis, tachypnoea, feeling of oppression, fever, chills, angioneurotic oedema and anaphylactic shock.

In some instances the precipitating agent will prove to be the preservative rather than the heparin itself.

Metabolic disorders:

Heparin administration is associated with release of lipoprotein lipase into the plasma; rebound hyperlipidaemia may follow heparin withdrawal.

Muscle and tissue disorders:

There is some evidence that prolonged dosing with heparin (i.e. over many months) may cause osteoporosis and fractures in the vertebra and ribs. Significant bone demineralisation has been reported in women taking more than 10,000 I.U. per day of heparin for three months or longer.

Reproductive and breast disorders:

Priapism has been reported.

Skin and subcutaneous tissue disorders:

Local irritation and skin necrosis may occur but are rare. There is some evidence that prolonged dosing with heparin (i.e. over many months) may cause alopecia.

Erythematous nodules, or infiltrated and sometimes eczema-like plaques, at the site of subcutaneous injections are common, occurring 3-21 days after starting heparin treatment.

Pruritus

Rash (including erythematous and maculopapular)

Vascular disorders:

Haematoma. Very rare cases of epidural and spinal haematoma have been reported in patients receiving heparin for prophylaxis undergoing spinal or epidural anaesthesia or spinal puncture.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9. Overdose

A potential hazard of heparin therapy is haemorrhage, but this is usually due to overdosage and the risk is minimised by strict laboratory control. Slight haemorrhage can usually be treated by withdrawing the drug. If bleeding is more severe, clotting time and platelet count should be determined. Prolonged clotting time will indicate the presence of an excessive anticoagulant effect requiring neutralisation by intravenous protamine sulfate, at a dosage of 1 mg for every 100 I.U. of heparin to be neutralised. The bolus dose of protamine sulfate should be given slowly over about 10 minutes and not exceed 50 mg. If more than 15 minutes have elapsed since the injection of heparin, lower doses of protamine will be necessary.

💬 Ask about this leaflet

Ask anything about Heparin sodium 25,000 I.U./ml solution for injection or concentrate for solution for infusion (with preservative) (PL 29831/0108). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →